Uvax Bio is a spin-off vaccine company that employs patented single-component self-assembling protein nanoparticle platform technology. It develops and commercializes B-cell focused, rapid antibody-eliciting, preventive vaccines for challenging diseases . The company delivers vaccine candidates to address human immunodeficiency viruses, respiratory syncytial virus, Ebola/Marburg, Lassa, coronaviruses, and non-viral diseases such as malaria and tuberculosis.